These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9554447)

  • 21. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
    Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
    Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics.
    Din S
    IDrugs; 2008 Dec; 11(12):855-6. PubMed ID: 19051141
    [No Abstract]   [Full Text] [Related]  

  • 23. Skeletal muscle anabolism in patients with advanced cancer.
    Baracos VE
    Lancet Oncol; 2015 Jan; 16(1):13-4. PubMed ID: 25524803
    [No Abstract]   [Full Text] [Related]  

  • 24. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
    Bai Y; Hu Y; Zhao Y; Yu X; Xu J; Hua Z; Zhao Z
    Support Care Cancer; 2017 May; 25(5):1651-1659. PubMed ID: 28074289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group.
    Loprinzi CL; Ellison NM; Goldberg RM; Michalak JC; Burch PA
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):8-12. PubMed ID: 2259930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.
    Loprinzi CL; Ellison NM; Schaid DJ; Krook JE; Athmann LM; Dose AM; Mailliard JA; Johnson PS; Ebbert LP; Geeraerts LH
    J Natl Cancer Inst; 1990 Jul; 82(13):1127-32. PubMed ID: 2193166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical management of anorexia and cachexia in patients with advanced cancer.
    Bruera E
    Oncology; 1992; 49 Suppl 2():35-42. PubMed ID: 1461626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydrazine sulfate: a current perspective.
    Gold J
    Nutr Cancer; 1987; 9(2-3):59-66. PubMed ID: 3104888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
    Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
    Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer cachexia: towards integrated therapeutic interventions.
    Molfino A; Formiconi A; Rossi Fanelli F; Muscaritoli M
    Expert Opin Biol Ther; 2014 Oct; 14(10):1379-81. PubMed ID: 25017968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life across cancer cachexia stages.
    Kasvis P; Vigano M; Vigano A
    Ann Palliat Med; 2019 Jan; 8(1):33-42. PubMed ID: 30525763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prokinetics and ghrelin for the management of cancer cachexia syndrome.
    Malik JS; Yennurajalingam S
    Ann Palliat Med; 2019 Jan; 8(1):80-85. PubMed ID: 30525771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide: dual benefits in palliative medicine and oncology.
    Davis MP; Dickerson ED
    Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
    Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
    Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
    Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
    Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer cachexia: it's time for more clinical trials.
    Bossola M; Pacelli F; Tortorelli A; Doglietto GB
    Ann Surg Oncol; 2007 Feb; 14(2):276-85. PubMed ID: 17094025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience.
    Chlebowski RT; Bulcavage L; Grosvenor M; Tsunokai R; Block JB; Heber D; Scrooc M; Chlebowski JS; Chi J; Oktay E
    Cancer; 1987 Feb; 59(3):406-10. PubMed ID: 3791153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of Anamorelin for the Treatment of Cancer Cachexia and Factors Associated with Weight Gain].
    Okuda Y; Saitoh T; Mikame Y; Shinada M; Fujimura S; Suga R; Kobayashi N; Nakata M; Arai D; Nakazawa T; Yamaguchi H; Imai Y
    Gan To Kagaku Ryoho; 2024 May; 51(5):529-533. PubMed ID: 38881063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer cachexia pathophysiology and translational aspect of herbal medicine.
    Suzuki H; Asakawa A; Amitani H; Fujitsuka N; Nakamura N; Inui A
    Jpn J Clin Oncol; 2013 Jul; 43(7):695-705. PubMed ID: 23737606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia: a Cancer and Leukemia Group B study.
    Laviano A; Muscaritoli M; Rossi-Fanelli F
    Cancer; 2005 Feb; 103(3):651-2. PubMed ID: 15578655
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.